Arcutis Biotherapeutics (ARQT) announced the submission of a supplemental new drug application to the FDA seeking to expand the indication for Zoryve cream 0.05% to include the topical treatment of mild to moderate atopic dermatitis in infants down to three months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
- Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
- Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
- Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
- Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline